No Data
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright analyst Joseph Pantginis maintains $Armata Pharmaceuticals(ARMP.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success
Analysts' Top Healthcare Picks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Armata Pharmaceuticals (ARMP)
Express News | Armata Pharmaceuticals Achieved Full Enrollment In Its Tailwind Phase 2 Study Of Inhaled AP-PA02 In Patients With NCFB And Chronic Pulmonary Pseudomonas Aeruginosa Infection, Topline Data Is Expected In The Second Half Of 2024
Express News | Armata Pharmaceuticals Inc -Phase 2 Topline Data Anticipated in 2H 2024 Followed by Potential Initiation of a Pivotal Bronchiectasis Trial in 2025
Express News | Armata Pharmaceuticals Inc - Last Patient Follow-up Visit Scheduled for August 7, 2024
Express News | Armata Pharmaceuticals Inc - Phase 2 Topline Data Anticipated in 2H 2024